Hi-Tech advancement in lifestyle and significant venture financing to compete with traditional pharmaceutical companies drive DTx expansion. They are software-based real curative interventions, a useful complement or in some cases replacement to biomedical therapeutics. However, how and when it will bring long-lasting change has yet to be determined.